Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010033868 - LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF

Publication Number WO/2010/033868
Publication Date 25.03.2010
International Application No. PCT/US2009/057580
International Filing Date 18.09.2009
IPC
C07K 4/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
4Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
C07K 7/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
C07K 14/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
CPC
A61P 31/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
20for DNA viruses
22for herpes viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C07K 16/2896
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2896against molecules with a "CD"-designation, not provided for elsewhere
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
Applicants
  • TALIGEN THERAPEUTICS, INC. [US]/[US] (AllExceptUS)
  • HOLERS, Michael, V. [US]/[US] (UsOnly)
  • HANNAN, Jonathan, P. [GB]/[GB] (UsOnly)
  • KOVACS, James [US]/[US] (UsOnly)
Inventors
  • HOLERS, Michael, V.
  • HANNAN, Jonathan, P.
  • KOVACS, James
Agents
  • HOFFMAN, David, C.
Priority Data
61/098,70819.09.2008US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF
(FR) COMPOSÉS SPÉCIFIQUES D'UN LIGAND QUI NE SONT PAS DES ANTICORPS ET QUI INHIBENT L'ACTIVATION DE CR2 ET PROCÉDÉS POUR LES UTILISER
Abstract
(EN) The present invention describes a novel non-antibody ligand- specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand' s binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.
(FR) La présente invention concerne un nouveau composé spécifique d'un ligand qui n'est pas un anticorps et qui se lie sélectivement à une protéine récepteur de complément type 2 (CR2), à un ligand de celle-ci, ou aux deux, le composé inhibant par compétition la liaison du ligand de CR2à une protéine CR2 dans un test standard. La présente invention concerne également des compositions et des procédés pour utiliser ce composé.
Related patent documents
Latest bibliographic data on file with the International Bureau